Related Experiment Video
Updated: Mar 15, 2026

High-Density Lipoprotein-Specific Phospholipid Efflux Assay
Published on: September 30, 2025
Recombinant high-density lipoproteins and their use in cardiovascular diseases
Yi-Ni Cao1, Lu Xu1, Ying-Chun Han1
1Peking University Institute of Cardiovascular Sciences, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China; Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, China.
Insights
High-density lipoprotein (HDL) therapies show promise for treating cardiovascular diseases like atherosclerosis. Recombinant HDL and apolipoproteins are key agents being studied for diagnosis and treatment.
Area of Science:
- Cardiovascular Medicine
- Biotechnology
- Pharmacology
Background:
- Cardiovascular diseases remain a leading cause of mortality worldwide.
- High-density lipoprotein (HDL) possesses unique anti-atherosclerosis and cardioprotective properties.
- HDL-based therapies have demonstrated good tolerability and future potential.
Purpose of the Study:
- To review novel HDL-based therapeutic agents for cardiovascular diseases.
- To highlight the diagnostic and therapeutic potential of recombinant HDL and apolipoproteins.
Main Methods:
- Review of current literature on HDL-based therapies.
- Discussion of specific agents including recombinant HDL, recombinant human apolipoproteins, apolipoprotein mimetic peptides, and HDL contrast agents.
Main Results:
- HDL-based therapies are well-tolerated and show significant therapeutic potential.
- Recombinant HDL and apolipoproteins are among the most studied agents.
- These agents show promise in both diagnosing and treating cardiovascular conditions.
Conclusions:
- HDL-based agents represent a promising frontier in cardiovascular disease management.
- Recombinant HDL and apolipoproteins are key players in the development of new diagnostic and therapeutic strategies.
- Further research into these agents could lead to improved patient outcomes.
Abstract:
The unique anti-atherosclerosis abilities and other cardioprotective properties make high-density lipoprotein (HDL) a promising solution in treating cardiovascular diseases. A number of studies showed that HDL-based therapy was well tolerated and has great potential in the future. Among all these new agents, the most studied ones including recombinant HDL, recombinant human apolipoproteins, apolipoprotein mimetic peptides and recombinant HDL used as contrast agents in cardiovascular imaging are discussed here. Recombinant HDL and apolipoproteins are promising in diagnosing and treating cardiovascular diseases.
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
Lipids: Dietary Sources and Requirements

